FTC OK's $324M Akorn Deal For Drugmaker, With Conditions
The Federal Trade Commission on Monday agreed to sign off on Akorn Inc.'s $324 million acquisition of private equity-backed niche drug manufacturer VersaPharm Inc. on the condition that Akorn sell its...To view the full article, register now.
Already a subscriber? Click here to view full article